Document is current
Any future updates will be listed below
-
Authors
Ryu, Min Hyung
Yun, Jeong H.
Kim, Kangjin
Gentili, Michele
Ghosh, Auyon
Sciurba, Frank
Barwick, Lucas
Limper, Andrew
Criner, Gerard
Brown, Kevin K.
Wise, Robert
Martinez, Fernando J.
Flaherty, Kevin R.
Cho, Michael H.
Castaldi, Peter J.
DeMeo, Dawn L.
Silverman, Edwin K.
Hersh, Craig P.
Morrow, Jarrett D.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (FRN:194027)
National Heart, Lung, and Blood Institute (K08 HL146972)
National Heart, Lung, and Blood Institute (R01HL162813)
National Heart, Lung, and Blood Institute (R01HL133135)
National Heart, Lung, and Blood Institute (R01HL166231)
National Heart, Lung, and Blood Institute (K25 HL136846)
Alpha-1 Foundation (Research Grant)
TOPMed (Fellowship)
- License Information
-
More Information
Article History
Received: 27 September 2024
Accepted: 11 November 2024
First Online: 18 December 2024
Declarations
:
: The participating centers’ Institutional Review Boards approved the study, and all subjects provided written informed consent.
: Not applicable.
: Dr. Hersh reports grant support from Bayer, Boehringer-Ingelheim, and Vertex, and consulting fees from Chiesi, Sanofi, and Takeda, unrelated to this manuscript. Dr. Silverman reports grant support from Bayer and Northpond Laboratories. Dr. Cho reports grant support from Bayer. Dr. DeMeo reports grant support from Bayer and Alpha-1 Foundation. Dr. Castaldi reports grant support from Bayer, Sanofi and consulting fees from Verona Pharmaceuticals. Dr. Yun reports grant support from Bayer and consulting fees from Bridge Biotherapeutics, and travel reimbursement from the Korean Academy of Tuberculosis and Respiratory Disease unrelated to this manuscript. Dr. Flaherty reports grant funding from Boehringer Ingelheim unrelated to this manuscript. Dr. Martinez reports grant supports from NHLBI, AstraZeneca, Chiesi, Boehringer-Ingelheim, GalaxoSmithCline, Novartis, Polarean, Sanofi/Regeneron, Sunovion, and TEVA Pharmaceuticals. Dr. Martinez reports receiving consulting fee from AstraZeneca, Boehringer-Ingelheim and Bristol Myers Squibb. Dr. Wise reports receiving consulting fees from Boehringer-Ingelheim, AstraZenica, Abb-Vie, and Galderma.
